ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1593

Epidemiology and Outcomes of Infection-related Hospitalizations in Young Adults with SLE: Data from National Inpatient Sample

Rashmi Dhital1, Monica Guma2, Dilli Poudel3 and Kenneth Kalunian4, 1UC San Diego, San Diego, CA, 2UCSD, La Jolla, CA, 3Indiana Regional Medical Center, Indiana, PA, 4University of California San Diego, La Jolla, CA

Meeting: ACR Convergence 2022

Keywords: Epidemiology, Infection, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Abstracts: SLE – Diagnosis, Manifestations, and Outcomes II: Complications

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: Infection is the leading cause of hospitalization and mortality in SLE. Care of young adults (YA) with SLE is particularly challenging, with higher mortality and disease activity noted in the immediate post-transition period from pediatric to adult rheumatology. Epidemiological studies focused on serious infection-related hospitalizations (SIH) in young adults with SLE (YA-SLE) are rare. In this study, we aimed to compare the infection rates, trends, patient characteristics, and outcomes for SIH by age categories in SLE, with a focus on young adults, using the largest publicly available all-payer inpatient database in the US, National Inpatient Sample (NIS).

Methods: We used NIS data from the years 2000-2019 to study the trends of SIH. The primary outcome was the rates of SIH in YA-SLE as compared to late adults with SLE (LA-SLE) and to young adults without SLE (YA-no SLE). STATA and Joinpoint Regression Program were used for analysis, and yearly changes in trends were calculated as annual percent change (APC).

Results: From 2010-2019, we identified a weighted national estimate of 1,732,467 hospitalizations with SLE in patients ≥13 years age. Of these, adolescents (13-17 years), young (18-24 years), late (25-49 years), and older adults (≥50 years) comprised on 9,990 (0.6%), 72,968 (4.2%), 647,438 (37.4%) and 1,002,072 (57.8%) hospitalizations, respectively Rates of SIH in YA-SLE were similar to LA-SLE (15% versus 14.7%, p=0.32), and considerably higher than YA- no SLE (15% versus 4.2%, p< 0.001) (Figure 1). Among SLE adults, septicemia, followed by pneumonia was the commonest primary diagnosis, accounting for ~ 45-50% and 20-25% of SIH, respectively. Significantly higher YA-SLE compared to LA-SLE and YA-no SLE comprised of non-white races, belonged to the lowest income quartile, and had Medicaid as their primary payer. The mean length of stay (LOS) and cost for YA-SLE were similar to LA-SLE and significantly higher than YA-no SLE (Table 1). In the 20-year period between 2000-2019, increasing trends of SIH in YA-SLE (APC 1.90, p< 0.05) LA-SLE (APC 2.62, p< 0.05) and YA- no SLE (APC 3.98, p< 0.05) (Figure 2), were all driven by increase in septicemia.

Conclusion: NIS is nationally representative and provides a readily available source of “real-world” health care data on a large population. Our results show that although young adults comprised a notably lower proportion of overall SLE hospitalizations compared to late adults, they have similar rates of SIH, and similar LOS and cost. Compared to late SLE adults, young SLE adults with SIH comprised of higher proportions of racial and socioeconomic minorities. Septicemia was the driver of the increasing trend of SIH.

Supporting image 1

Figure 1: Comparison of rates of serious infection-related hospitalizations (SIH) among different age categories of SLE and non-SLE patients. Adolescents (13_17), young adults (18_24), late adults (25_49), and older adults (≥50 years)

Supporting image 2

Table 1: Baseline characteristics and hospitalization outcomes of serious infection-related hospitalizations (SIH) among young adults and late adults with SLE

Supporting image 3

Figure 2: Trends of serious infection-related hospitalizations (SIH) among different age categories of SLE. Ad: Adolescents (13_17), YA: young adults (18_24), LA: late adults (25_49), and OA: older adults (≥50 years).
The rate of change in annual trend, calculated using Joinpoint regression software, is expressed as Annual Percent Change (APC), *p<0.05


Disclosures: R. Dhital, None; M. Guma, Pfizer, Novartis, Gilead, Sonoma Bio, Genentech; D. Poudel, None; K. Kalunian, AbbVie/Abbott, Amgen, AstraZeneca, Aurinia, Biogen, Bristol Myers Squibb (BMS), Eli Lilly, Equillium, Genentech, Gilead, Janssen, Roche, Lupus Research Alliance, Pfizer, Sanford Consortium, Viela, Nektar.

To cite this abstract in AMA style:

Dhital R, Guma M, Poudel D, Kalunian K. Epidemiology and Outcomes of Infection-related Hospitalizations in Young Adults with SLE: Data from National Inpatient Sample [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/epidemiology-and-outcomes-of-infection-related-hospitalizations-in-young-adults-with-sle-data-from-national-inpatient-sample/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/epidemiology-and-outcomes-of-infection-related-hospitalizations-in-young-adults-with-sle-data-from-national-inpatient-sample/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology